Influence of NQO1 Polymorphisms on Warfarin Maintenance Dose: A Systematic Review and Meta-Analysis (rs1800566 and rs10517)

Tian, Lihong; Xiao, Peipei; Zhou, Biying; Chen, Yishan; Kang, Lijuan; Wang, Qingqing; Lin, Jie; Son, Min Ji; Wu, Qianni

doi:10.1155/2021/5534946

Cited by 8 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of the NQO1 rs1800566 T/T genotype is 4% to 20%, depending on the ethnic group, with the highest prevalence in Asian populations (Kelsey et al., 1997 ), especially in Japan. NQO1 rs10517, like the NQO1 rs1800566 polymorphism, affects warfarin metabolism by affecting NQO1 function (Tian et al., 2021 ). NQO1 rs689452 is an intronic polymorphism located in a protein‐binding motif with the potential to modulate NQO1 protein activity.…”

Section: Discussionmentioning

confidence: 99%

“…In particular, the NQO1 rs1800566 polymorphism (c.559C>T, p. Pro187Ser) (Lienhart et al., 2014 ), which is common in the Japanese population (Table 1 ), may be associated with the development of SMON. In this study, we analyzed the NQO1 rs1800566 polymorphism and other previously reported loss‐of‐function polymorphisms in NQO1 , rs10517 (c.*1119 T>C; 3′ UTR variant) (Tian et al., 2021 ), rs689452 (c.8‐27G>C; intron variant) (Hemissi et al., 2021 ), and rs689456 (c.‐1221G>A; upstream transcript variant) (Reddy et al., 2009 ), using genomic data for patients with SMON.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy

Matsumoto,

Sasai,

Kawamoto

et al. 2024

Molec Gen & Gen Med

View full text Add to dashboard Cite

BackgroundSubacute myelo‐optico‐neuropathy (SMON) is a neurological disorder associated with the administration of clioquinol, particularly at very high doses. Although clioquinol has been used worldwide, there was an outbreak of SMON in the 1950s–1970s in which the majority of cases were in Japan, prompting speculation that the unique genetic background of the Japanese population may have contributed to the development of SMON. Recently, a possible association between loss‐of‐function polymorphisms in NQO1 and the development of SMON has been reported. In this study, we analyzed the relationship between NQO1 polymorphisms and SMON in Japan.MethodsWe analyzed 125 Japanese patients with SMON. NQO1 loss‐of‐function polymorphisms (rs1800566, rs10517, rs689452, and rs689456) were evaluated. The allele frequency distribution of each polymorphism was compared between the patients and the healthy Japanese individuals (Human Genomic Variation Database and Integrative Japanese Genome Variation Database), as well as our in‐house healthy controls.ResultsThe frequencies of the loss‐of‐function NQO1 alleles in patients with SMON and the normal control group did not differ significantly.ConclusionWe conclude that known NQO1 polymorphisms are not associated with the development of SMON.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy

Matsumoto,

Sasai,

Kawamoto

et al. 2024

Molec Gen & Gen Med

View full text Add to dashboard Cite

show abstract

“…In fact, closely-related NQO1, that uses NADH, a typical co-substrate for oxidoreduction reaction, is at least ten times more studied with regard to polymorphic variants than NQO2. Recent systemic reviews confirm that NQO1 PGx is much more advanced compared to NQO2 PGx and addresses specific topics [113][114][115]. We can expect that a better grasp of the regulatory mechanisms of NQO2 enzymatic activity would trigger a stronger interest and faster progress in our understanding of NQO2 genetics, biology and pharmacology in the future.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future

Janda,

Boutin,

De Lorenzo

et al. 2024

Genes

View full text Add to dashboard Cite

The flavoenzyme N-ribosyldihydronicotinamide (NRH):quinone oxidoreductase 2 (NQO2) catalyzes two-electron reductions of quinones. NQO2 contributes to the metabolism of biogenic and xenobiotic quinones, including a wide range of antitumor drugs, with both toxifying and detoxifying functions. Moreover, NQO2 activity can be inhibited by several compounds, including drugs and phytochemicals such as flavonoids. NQO2 may play important roles that go beyond quinone metabolism and include the regulation of oxidative stress, inflammation, and autophagy, with implications in carcinogenesis and neurodegeneration. NQO2 is a highly polymorphic gene with several allelic variants, including insertions (I), deletions (D) and single-nucleotide (SNP) polymorphisms located mainly in the promoter, but also in other regulatory regions and exons. This is the first systematic review of the literature reporting on NQO2 gene variants as risk factors in degenerative diseases or drug adverse effects. In particular, hypomorphic 29 bp I alleles have been linked to breast and other solid cancer susceptibility as well as to interindividual variability in response to chemotherapy. On the other hand, hypermorphic polymorphisms were associated with Parkinson’s and Alzheimer’s disease. The I and D promoter variants and other NQO2 polymorphisms may impact cognitive decline, alcoholism and toxicity of several nervous system drugs. Future studies are required to fill several gaps in NQO2 research.

show abstract

“…These reviews assessed patients receiving OACs for any condition, including cardiomyopathy, heart-valve replacement, and rheumatic heart disease, as well as AF or VTE (see Additional file 4 for details). The update searches identified seven reviews [36][37][38][39][40][41][42] that met the inclusion criteria (see Additional file 4 for details). One [38] of these reported data for patients with AF.…”

Section: Genotypingmentioning

confidence: 99%

Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences

Khouja

Brunton²,

Richardson³

et al. 2022

Syst Rev

View full text Add to dashboard Cite

Background This systematic overview was commissioned by England’s Department of Health and Social Care (DHSC) to assess the evidence on direct (previously ‘novel’) oral anticoagulants (OACs), compared with usual care, in adults, to prevent stroke related to atrial fibrillation (AF), and to prevent and treat venous thromboembolism (VTE). Specifically, to assess efficacy and safety, genotyping, self-monitoring, and patient and clinician experiences of OACs. Methods We searched MEDLINE, Embase, ASSIA, and CINAHL, in October, 2017, updated in November 2021. We included systematic reviews, published from 2014, in English, assessing OACs, in adults. We rated review quality using AMSTAR2 or the JBI checklist. Two reviewers extracted and synthesised the main findings from the included reviews. Results We included 49 systematic reviews; one evaluated efficacy, safety, and cost-effectiveness, 17 assessed genotyping, 23 self-monitoring or adherence, and 15 experiences (seven assessed two topics). Generally, the direct OACs, particularly apixaban (5 mg twice daily), were more effective and safer than warfarin in preventing AF-related stroke. For VTE, there was little evidence of differences in efficacy between direct OACs and low-molecular-weight heparin (prevention), warfarin (treatment), and warfarin or aspirin (secondary prevention). The evidence suggested that some direct OACs may reduce the risk of bleeding, compared with warfarin. One review of genotype-guided warfarin dosing assessed AF patients; no significant differences in stroke prevention were reported. Education about OACs, in patients with AF, could improve adherence. Pharmacist management of coagulation may be better than primary care management. Patients were more adherent to direct OACs than warfarin. Drug efficacy was highly valued by patients and most clinicians, followed by safety. No other factors consistently affected patients’ choice of anticoagulant and adherence to treatment. Patients were more satisfied with direct OACs than warfarin. Conclusions For stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5 mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and VTE. Systematic review registration PROSPERO CRD42017084263—one deviation; efficacy and safety were from one review.

show abstract

Influence of NQO1 Polymorphisms on Warfarin Maintenance Dose: A Systematic Review and Meta-Analysis (rs1800566 and rs10517)

Cited by 8 publications

References 36 publications

Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy

Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy

Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future

Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences

Contact Info

Product

Resources

About